Lisata Therapeutics, Inc. $LSTA

What the company doesAI summary of filing

Lisata Therapeutics is a clinical-stage pharmaceutical company developing certepetide, an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors by activating a novel tumor-specific transport mechanism called the C-end rule active transport pathway. The company is studying certepetide in combination with chemotherapy and immunotherapy across multiple Phase 2 clinical trials for cancers including metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, and glioblastoma multiforme. Lisata has not generated revenue from product sales; it is pre-revenue and relies on clinical development activities. As of March 2026, the company agreed to be acquired by Kuva Labs Inc. for $5.00 per share in cash plus a contingent payment of $1.00 per share if an FDA filing occurs for certepetide within seven years. [10-K 2026-03-12]

Segments: Certepetide (CendR Platform)